Allarity Therapeutics Europe ApS
CVR 34623562 · Private limited company (ApS) · Active · Medium risk
Allarity Therapeutics Europe ApS is a Private limited company (ApS), founded on , based in Hørsholm. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 2.6% over the next 12 months, which is 1.9 times the average for Danish companies. 13 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -216.6m and a net result of DKK -17.8m. CEO: Jeffrey Stuart Ervin.
Bankruptcy risk for Allarity Therapeutics Europe ApS
1.9 × the average (1.41%) · higher risk than 86% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34623562
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (14 years)
- Address
- Venlighedsvej 1
2970 Hørsholm - Municipality
- Rudersdal
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 2.2m
- Employees
- 6 (2018)
- Auditor
- Cedra Godkendt Revisionsaktieselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 5 of 13 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -839.3% |
| Current ratio | 10% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 12 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 3 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -39.0m | DKK -44.5m | DKK -49.4m |
| Net profit | DKK -17.8m | DKK -393.8m | DKK -48.7m |
| Equity | DKK -216.6m | DKK -198.8m | DKK 195.0m |
| Total assets | DKK 25.8m | DKK 11.2m | DKK 362.2m |
| Cash | DKK 2.0m | DKK 575k | – |
| Short-term debt | DKK 242.4m | DKK 210.0m | – |
| Avg. employees | 4 | 4 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · Deloitte.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 187 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 184 | Late | |
| 1 Jan 2023 – 31 Dec 2023 | 180 | ||
| 1 Jan 2022 – 31 Dec 2022 | 183 | ||
| 1 Jan 2021 – 31 Dec 2021 | 208 | Late | |
| 1 Jan 2020 – 31 Dec 2020 | 186 | Late | |
| 1 Jan 2019 – 31 Dec 2019 | 178 | ||
| 1 Jan 2018 – 31 Dec 2018 | 163 | ||
| 1 Jan 2017 – 31 Dec 2017 | 170 | ||
| 1 Jan 2016 – 31 Dec 2016 | 158 | ||
| 1 Jan 2015 – 31 Dec 2015 | 149 | ||
| 1 Jan 2014 – 31 Dec 2014 | 140 | ||
| 1 Aug 2012 – 31 Dec 2013 | 170 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Jeffrey Stuart Ervin | Current | |
| CEO | Peter Buhl | ||
| CEO | Jens Erik Knudsen | ||
| CEO | James G. Cullem | ||
| CEO | Joan Yvonne Brown | ||
| CEO | Steen Meier Knudsen | ||
| CEO | Alexander Epshinsky | ||
| Board | Ulla Hald Buhl | ||
| Board | Jørgen Søberg Petersen | ||
| Board | Peter Birk Rasmussen | ||
| Board | Duncan Charles McNaught Moore | ||
| Board | Carani Balarman Sanjeevi | ||
| Board | Steen Meier Knudsen | ||
| Owner (100%) | Allarity Acquisition Subsidiary, Inc. | Current | |
| Owner (20%) | BUHL KRONE HOLDING ApS | ||
| Owner (20%) | Allarity Therapeutics A/S | ||
| Owner (5%) | TIMPCO NB ApS | ||
| Owner (15%) | Styrelsen for Forskning og Uddannelse | ||
| Owner (15%) | SASS & LARSEN ApS | ||
| Owner (100%) | Oncology Venture Sweden AB | ||
| Owner (100%) | Allarity Therapeutics A/S | ||
| Auditor | Cedra Godkendt Revisionsaktieselskab | Current | |
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Auditor | EY Godkendt Revisionspartnerselskab | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | BUHL KRONE HOLDING ApS | Current |
The CEOs' other companies
Peter Buhl – 19 other companies, of which 1 bankrupt
- UDVIKLINGSSELSKABET LP AF 11. JANUAR 2001 A/S Bankrupt 2 Dec 2009
- 4 BEST INVEST ApS Fusioneret
- ACCELERACE MANAGEMENT A/S Active
- ANTIANTHRA ApS Fusioneret
- Allarity Therapeutics A/S Opløst
- Allarity Therapeutics Denmark ApS Active
- AÏDA ONCOLOGY Aps Active
- BUHL KRONE HOLDING ApS Active
- Bagger-Sørensen Real Estate A/S Active
- CYTOGUIDE ApS Opløst
- IT-VÆKSTHUS A/S Fusioneret
- LIPLASOME PHARMA ApS Active
- Ranger Biotechnologies A/S Active
- Renovaro Biosciences Denmark ApS Active
- SYMBION A/S Active
- SYMBION MANAGEMENT A/S Fusioneret
- Symbion Frederiksberg A/S Active
- TOPOTARGET A/S Fusioneret
- VECATA INVEST ApS Fusioneret
Jens Erik Knudsen – 2 other companies
- Allarity Therapeutics A/S Opløst
- Allarity Therapeutics Denmark ApS Active
Steen Meier Knudsen – 4 other companies
- AUTOMATIC SYD HANDEL ApS Opløst
- Allarity Therapeutics A/S Opløst
- Allarity Therapeutics Denmark ApS Active
- MPI HOLDING ApS Opløst
Address history (1 moves)
| Venlighedsvej 1, 2970 Hørsholm | |
| Skovbakken 54, 3520 Farum |
Former names
| Allarity Therapeutics Europe ApS | – now |
| Oncology Venture Product Development ApS | – |
| ONCOLOGY VENTURE ApS | – |
Employees per year
Other companies at the same address
- Allarity Therapeutics A/S Opløst
- Allarity Therapeutics Denmark ApS Active
- Semantic ApS Active
Similar companies in Rudersdal
- ALK-ABELLÓ A/S Hørsholm
- AleSac ApS Holte
- Breye Therapeutics ApS Hørsholm
- Remecure ApS Holte
- Allarity Therapeutics Denmark ApS Hørsholm
- SYNACT PHARMA ApS Holte
- SCANPHARM A/S Birkerød
- Højbo Healthcare ApS Vedbæk
- Bacthera Denmark A/S Hørsholm
- AddMe Consulting ApS Vedbæk
- Inpare ApS Hørsholm
Questions and answers about Allarity Therapeutics Europe ApS
Has Allarity Therapeutics Europe ApS gone bankrupt?
No, Allarity Therapeutics Europe ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Allarity Therapeutics Europe ApS?
Our model estimates a bankruptcy risk of 2.6% over the next 12 months (medium risk), which is 1.9 times the average for Danish companies.
Who is the CEO of Allarity Therapeutics Europe ApS?
Jeffrey Stuart Ervin is the CEO of Allarity Therapeutics Europe ApS.
Who is the auditor of Allarity Therapeutics Europe ApS?
Allarity Therapeutics Europe ApS most recently used Cedra Godkendt Revisionsaktieselskab.
When was Allarity Therapeutics Europe ApS founded?
Allarity Therapeutics Europe ApS was founded on 1 August 2012.
What is the equity of Allarity Therapeutics Europe ApS?
Equity was DKK -216.6m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.